Bilcare Research Inc., a division of one of the world’s largest manufacturers of blister packaging solutions, has begun segregating pharma-related production operations from those servicing other industries at its Wilmington, DE facility. The decision showcases Bilcare‘s commitment to the pharmaceutical sector amid growing customer demand and heightened quality control expectations.
Part of the global Pharmaceutical Packaging Innovation (PPI) Business Unit of Bilcare Research AG, Bilcare Research offers a variety of mono and barrier blister films to the pharmaceutical packaging industry. In addition to manufacturing pharmaceutical blister films, the company also produces products for other business units of the company.
With growing customer demand and a steadily increasing market share in the pharmaceutical films sector, Bilcare’s effort to separate its PPI production and storage area from areas servicing other businesses has the purpose of clearly differentiating its production process along industry-specific lines. The result is the ability to service all sectors more efficiently.
“We are dedicated to our pharmaceutical customers and this is just one more example of how,” said Kevin Stevens, President and Managing Director of Bilcare Research Inc. “Our strategy is to exceed our customers’ expectations in the quality of Bilcare’s products; the new plant layout shows our commitment and investment to that end. Packaging pharmaceutical products in an ideal fashion calls for a dedicated, siloed production environment throughout the supply chain, and we aim to set the bar high toward that goal.”